Funding for this research was provided by:
Canadian Institutes of Health Research (Canadian Institutes of Health Research)
Canadian HIV Trials Network, Canadian Institutes of Health Research (Canadian HIV Trials Network, Canadian Institutes of Health Research)
Received: 29 November 2020
Accepted: 3 June 2021
First Online: 30 June 2021
: Research ethics board approval for the patient exit-interviews was obtained from the Research Ethics Board at the University Health Network, Ottawa Health Science Network, Unity Health Toronto, Sunnybrook Health Sciences Centre, University of Toronto, and from the Public Health Ontario Ethics Review Board. Each research participant interviewed for this patient process evaluation provided informed and written consent indicating consent for publication. Informed consent forms signed by participants received approval by the research ethics boards.
: Not applicable.
: DHST has received investigator-initiated research grants from Gilead Sciences and Viiv Healthcare, and is a site principal investigator for clinical trials sponsored by Glaxo Smith Kline. SW has spoken at continuing medical education events, served on advisory boards and participated in clinical trials with Gilead, Viiv, Jannsen, and Merck. All other authors declare that they have no competing interests.